Randomized phase III trial of retinoic acid and arsenic trioxide versus retinoic acid and chemotherapy in patients with acute promyelocytic leukemia: health-related quality-of-life outcomes.
暂无分享,去创建一个
R. Schlenk | A. Levis | M. Vignetti | F. Mandelli | F. Lo‐Coco | G. Avvisati | F. Ferrara | F. Cottone | U. Platzbecker | S. Amadori | F. Efficace | G. Fioritoni | M. Breccia | G. Specchia | S. Sica | E. di Bona | M. Kropp | E. Cerqui | O. Finizio
[1] Saijuan Chen,et al. Oral tetra-arsenic tetra-sulfide formula versus intravenous arsenic trioxide as first-line treatment of acute promyelocytic leukemia: a multicenter randomized controlled trial. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] E. Basch. Toward patient-centered drug development in oncology. , 2013, New England Journal of Medicine.
[3] Paola Fazi,et al. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. , 2013, The New England journal of medicine.
[4] D. Patrick. Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension. , 2013, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[5] R. Hills,et al. Inclusion of chemotherapy in addition to anthracycline in the treatment of acute promyelocytic leukaemia does not improve outcomes: results of the MRC AML15 trial , 2013, Leukemia.
[6] D. Moher,et al. Patient-reported outcomes in randomized clinical trials: development of ISOQOL reporting standards , 2012, Quality of Life Research.
[7] F. Lo‐Coco,et al. Arsenic trioxide for management of acute promyelocytic leukemia: current evidence on its role in front-line therapy and recurrent disease , 2012, Expert opinion on pharmacotherapy.
[8] F. Bonnetain,et al. Impact of response shift on longitudinal quality-of-life assessment in cancer clinical trials , 2011, Expert review of pharmacoeconomics & outcomes research.
[9] K. Alimoghaddam,et al. Phase II study of single-agent arsenic trioxide for the front-line therapy of acute promyelocytic leukemia. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] Ethan Basch,et al. The missing voice of patients in drug-safety reporting. , 2010, The New England journal of medicine.
[11] M. Tallman,et al. How I treat acute promyelocytic leukemia. , 2009, Blood.
[12] P. Dickman,et al. Improved patient survival for acute myeloid leukemia: a population-based study of 9729 patients diagnosed in Sweden between 1973 and 2005. , 2009, Blood.
[13] E. Estey,et al. Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. , 2009, Blood.
[14] S. Molica,et al. Health-related quality of life assessment and reported outcomes in leukaemia randomised controlled trials - a systematic review to evaluate the added value in supporting clinical decision making. , 2008, European journal of cancer.
[15] Zhen-yi Wang,et al. Acute promyelocytic leukemia: from highly fatal to highly curable. , 2008, Blood.
[16] J. Radich,et al. End points to establish the efficacy of new agents in the treatment of acute leukemia. , 2007, Blood.
[17] D. Osoba,et al. Has the quality of health-related quality of life reporting in cancer clinical trials improved over time? Towards bridging the gap with clinical decision making. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.
[18] A. Bowling. Mode of questionnaire administration can have serious effects on data quality. , 2005, Journal of public health.
[19] Alberto Redaelli,et al. Short- and long-term effects of acute myeloid leukemia on patient health-related quality of life. , 2004, Cancer treatment reviews.
[20] D. Osoba,et al. Beyond the development of health-related quality-of-life (HRQOL) measures: a checklist for evaluating HRQOL outcomes in cancer clinical trials--does HRQOL evaluation in prostate cancer research inform clinical decision making? , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] W. Berdel,et al. Fatigue as an important aspect of quality of life in patients with acute myeloid leukemia. , 2002, Leukemia research.
[22] D. Fairclough. Design and analysis of quality of life studies in clinical trials , 2002, Quality of Life Research.
[23] D. Osoba,et al. Missing quality of life data in cancer clinical trials: serious problems and challenges. , 1998, Statistics in medicine.
[24] Suciu,et al. Cost‐effectiveness and quality‐of‐life assessment of GM‐CSF as an adjunct to intensive remission induction chemotherapy in elderly patients with acute myeloid leukaemia , 1998 .
[25] P. Fayers,et al. Evidence-based guidelines for determination of sample size and interpretation of the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] E. Estey,et al. Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] P. Loehrer. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial , 2008 .
[28] Ross Camidge,et al. The European Organisation for Research and Treatment of Cancer , 2002 .
[29] E. Vellenga,et al. Cost-effectiveness and quality-of-life assessment of GM-CSF as an adjunct to intensive remission induction chemotherapy in elderly patients with acute myeloid leukemia. , 1998, British journal of haematology.
[30] Andrew Bottomley,et al. EORTC QLQ-C30 Scoring Manual , 1995 .